Navigation Links
Vasoguard Vascular Doppler

ProductsVasoguard Vascular Doppler
Company VIASYS Healthcare (Nicolet Biomedical)
Item Vasoguard Vascular Doppler
Features 
  • Fully integrated, PC based vascular system
  • High resolution 18" SVGA LCD flat panel display
  • Thumb-Nail Reports
  • Simultaneous 10-cuff inflation
  • QuickConnect 10 color coded hoses
  • Complete Blood Pressure Cuff Set
  • Integrated keyboard trackball/mouse
  • True Windows Software
  • Complete Waveform Scrolling
  • Superior Doppler sensitivity using SSD technology
  • High-resolution color Doppler spectral analysis
  • Full range of test modalities
Description The VasoGuard from VIASYS Neurocare - continues the revolutionary leap forward in physiologic vascular diagnosis. Exceptional convenience and speed. Superior Doppler sensitivity and system reliability.

VasoGuard delivers features you won't find anywhere else. The unique QuickConnect arm for cuff attachment and testing. Up to 10-channel simultaneous PVR measurements. A super-high-resolution graphic display. Unsurpassed Doppler performance. And behind it all - an integrated PC running Windows XP and our exclusive V-LINK interface.

Info VIASYS Healthcare (Nicolet Biomedical)
Customer Service: (800) 356-0007
Web site: http://www.nicoletbiomedical.com/

Related medicine products :

1. Vasoguard Microlite Vascular Doppler
2. Vascular Clamps B-1
3. Vascular Clamps B-2
4. Vascular Clamps B-3
5. Vascular Clamps HD-S
6. Vascular Clamps RD-S
7. Vascular Clamps ABB-11
8. VersaLab Vascular Doppler
9. PINNACLE Introducer Sheath Designed for Vascular Access
10. CVS4 Complete Vascular System
11. GORE-TEX INTERING Vascular Graft-Peripheral Thin Walled Stretch
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Steaz Launches Organic Zero Calorie Sparkling Line 59893 1Steaz Launches Organic Zero Calorie Sparkling Line 59893 2Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday November 4 at 10 A M EST 59891 1Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday November 4 at 10 A M EST 59891 2Bioidentical Hormones a True Prevention for Breast Cancer 59889 1Bioidentical Hormones a True Prevention for Breast Cancer 59889 2